CN107254472A - 人表皮生长因子hEGF基因优化序列及其制备方法和应用 - Google Patents
人表皮生长因子hEGF基因优化序列及其制备方法和应用 Download PDFInfo
- Publication number
- CN107254472A CN107254472A CN201710451539.2A CN201710451539A CN107254472A CN 107254472 A CN107254472 A CN 107254472A CN 201710451539 A CN201710451539 A CN 201710451539A CN 107254472 A CN107254472 A CN 107254472A
- Authority
- CN
- China
- Prior art keywords
- hegf
- optimization
- gene
- gene optimization
- restriction enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 52
- 238000005457 optimization Methods 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 241000588724 Escherichia coli Species 0.000 claims abstract description 9
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 6
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 5
- 108091008146 restriction endonucleases Proteins 0.000 claims description 15
- 239000013612 plasmid Substances 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 7
- 108020004705 Codon Proteins 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 108010042407 Endonucleases Proteins 0.000 claims description 2
- 102000004533 Endonucleases Human genes 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 abstract description 13
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract description 12
- 230000014509 gene expression Effects 0.000 abstract description 11
- 230000009465 prokaryotic expression Effects 0.000 abstract description 4
- 108700010070 Codon Usage Proteins 0.000 abstract description 2
- 238000006073 displacement reaction Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 210000003000 inclusion body Anatomy 0.000 description 12
- 230000006698 induction Effects 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000007792 addition Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 102400001368 Epidermal growth factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 241000025995 Chone Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101000851196 Mus musculus Pro-epidermal growth factor Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/86—Products or compounds obtained by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种人表皮生长因子hEGF基因优化序列及其制备方法和应用,所述优化序列如SEQIDNO.1所示。本发明通过改变EGF基因的cDNA结构,同义密码子置换核苷酸序列中个别基因的碱基,选择了一种密码子偏好性最优的合成EGF优化序列,构建原核表达载体pET‑30a‑hEGF使其在大肠杆菌宿主中能够得到高水平的表达。对EGF产业化生产及其应用具有重要意义。
Description
技术领域
本发明属于生物技术领域,具体涉及一种人表皮生长因子hEGF基因优化序列及其制备方法和应用。
背景技术
EGF是继神经生长因子之后发现的第二个生长因子,1959年由Chone首先从小鼠领下腺中分离出来,因为能够促进小鼠门齿的萌出及眼睑睁开,最初被称为“齿睑因子”。随后发现这种多肽能够促进表皮生长,又将其命名为表皮生长因子(即小鼠表皮生长因子,mEGF)121。1975年Gergoyr从人尿中提取出一种具有抑制胃酸分泌的物质称为尿抑胃素(urogastrone),后来证实尿抑胃素即人EGF(hEGF)。
hEGF含有53个氨基酸残基,分子量为6200Da,沉降系数1.255,等电点pH4.7,含3个链内二硫键,是多肤生长因子中最小的一个。相对于其它多肤类物质,EGF对酸和热均较稳定,是已知的最稳定的蛋白多肽之一。hEGF系一单链多肤,圆二色谱研究表明,hEGF没有α螺旋,β片层结构占22%。在整个hEGF分子中,主要折叠为两个结构域:1-32氨基酸残基区域为N- 端结构域,33-53氨基酸残基区域为C-端结构域。其中22-32残基区和33-53残基区直接参与EGF 与其受体的结合,前者起信号转导作用,后者起稳定作用。
hEGF能促进烧伤、创伤及外科伤的愈合,在烧伤、创伤、皮肤和角膜移植、外伤性皮肤溃疡等治疗中有重要作用。EGF也是某些化妆品的添加剂,具有较大的市场价值。目前利用原核***表达重组hEGF(rhEGF)的主要弊端是表达量较低,生物活性不高,真核表达周期长,操作繁琐,成本高等缺点很难规模化生产。
发明内容
解决的技术问题:本发明的目的是解决现有原核***表达重组hEGF(rhEGF)表达量较低、生物活性不高、操作繁琐、成本高的技术问题,提供一种人表皮生长因子hEGF基因优化序列及其制备方法和应用。
技术方案:人表皮生长因子hEGF基因优化序列,如SEQIDNO.1所示。
上述人表皮生长因子hEGF基因优化序列的制备方法,包括以下步骤:
步骤1,在基因数据库中获取人表皮生长因子hEGF基因;
步骤2,基因优化:对人表皮生长因子hEGF基因的编码区进行大肠杆菌密码子偏爱性的基因优化得到优化序列,优化序列编码的氨基酸与人表皮生长因子hEGF基因编码形成的氨基酸序列一致;
步骤3,添加酶切位点:在优化序列的5’端添加一种内切酶的酶切位点,在优化序列的3’端添加另一种内切酶酶切位点,得到合成序列;
步骤4,基因合成:对得到的合成序列进行全基因合成。
进一步地,在步骤3中,优化序列的5’端添加NdeI酶切位点,优化序列的3’端添加XhoI酶切位点。
含有上述人表皮生长因子hEGF基因优化序列的质粒。
进一步地,所述质粒为pET-30a质粒。
进一步地,上述人表皮生长因子hEGF基因优化序列***到pET-30a质粒的Nde I酶切位点和Xho I酶切位点之间。
含有上述人表皮生长因子hEGF基因优化序列的原核生物。
进一步地,所述原核生物为大肠杆菌。
上述人表皮生长因子hEGF基因优化序列表达得到的人表皮生长因子hEGF在制备护肤品中的应用。
有益效果:利用本发明的人表皮生长因子hEGF基因优化序列可实现原核细菌宿主工程菌 EGF蛋白的高表达,并且具有较高的生物学活性:1、其表达量约占总蛋白的30%左右,以包涵体的形式表达,复性成功的前体下包涵体处理相对较容易;2、通过纯化后,得到纯度在95%左右的EGF小肽,并且依据中国药典2010版中的重组人表皮生长因子生物学活性测定方法,检测了生物学活性,活性大于药典标准1×105UI。
附图说明
图1为实施例1中人表皮生长因子hEGF优化基因扩增琼脂糖凝胶电泳图;
图2为实施例2中人表皮生长因子hEGF蛋白表达鉴定SDS-PAGE电泳图;
图3为实施例2中人表皮生长因子hEGF蛋白纯化SDS-PAGE电泳图;
图4为实施例3中人表皮生长因子hEGF蛋白MTT法活性检测吸光值统计图。
具体实施方式
下面通过具体实施方式对发明作进一步详细说明。但本领域技术人员将会理解下列实施例仅用于说明本发明,而不应视为限定本发明的范围。
实施例1
人表皮生长因子hEGF的基因优化方法
登录GeneBank,查找人表皮生长因子hEGF活性肽的基因序列,其核酸长度为159bp, hEGF为真核生物多肽序列,考虑到后续研发在原核中进行表达,因此将上述hEGF真核多肽序列的编码密码子与大肠杆菌偏好性密码子进行比较分析。根据密码子的兼并性和不改变 hEGF活性肽氨基酸排列顺序不变的情况下,参照生物软件Vector NTI Suitor 7.0对hEGF核酸序列进行分析,对已知的hEGF进行基因改造优化,主要是将hEGF原基因序列中大肠杆菌稀有的密码子改成偏好的密码子,以提高目的基因在大肠杆菌的高水平表达。并进行转基因验证,最终得到hEGF基因的优化序列如SEQIDNO.1所示。
将人hEGF基因优化序列N端和C端分别加上NdeⅠ和XhoⅠ酶切位点。送上海生工公司进行全基因合成,PCR扩增基因后(如图1所示,基因片段大小正确)并连入原核表达载体pET-30a(军事医学科学院馈赠)的NdeⅠ和XhoⅠ酶切位点之间,得到重组的原核表达质粒pET-30a-hEGF。
实施例2
2.1表达菌株的获得
将实施例1中的得到的原核表达载体pET-30a-hEGF通过热激法转入大肠杆菌BL21(DE3)(购自于天根生物公司)中,LB平板培养基中加入卡那霉素50ug/mL进行筛选,挑选单克隆进行测序确认鉴定。
2.2人表皮生长因子hEGF基因优化序列的诱导表达
将重组阳性单克隆菌落接种到含有浓度为50ug/mL卡那霉素的LB液体培养基中,37℃, 220rpm振荡培养过夜,按照1%的比例将过夜培养的菌液接种到含有50ug/mL卡那霉素的新鲜的液体培养基中,37℃,220rpm培养至菌液浓度OD600约为0.9,立即加入诱导剂IPTG 至0.5Mm,将诱导组和对照组继续培养3h,12000rpm,离心10min收集菌体。
2.3人表皮生长因子hEGF提取与鉴定
将离心收集的菌体,按照每克菌体湿重加入10mL的PBS缓冲液重选菌体,充分混匀,用终浓度为1mg/mL的溶菌酶溶液4℃过夜消化菌体。处理后的菌体于冰上超声破碎,超声 5s,间隔5s,总用15min,然后4℃,12000rpm离心30min。取包涵体沉淀,用1%的Triton-x-100 洗涤3遍,得到粗纯后的包涵体进一步纯化。对未诱导包涵体和诱导后包涵体进行SDA-PAGE 分析,结果如图2所示:M为标准蛋白分子1、未诱导包涵体组份;2、诱导后包涵体组份。根据分子量大小可知诱导后多出来的蛋白条带就是hEGF蛋白。
采用Ni-NTA琼脂糖亲和层析柱纯化人表皮生长因子hEGF,先用5倍柱床体积平衡液缓冲液(8M尿素,100mM NaH2PO4,100mM Tris-Hcl pH=8)平衡层析柱,将上述hEGF样品按照1mL/min的流速上柱。当样品全部过完介质后,加入清洗缓冲液(8M尿素,100mM NaH2PO4,100mM Tris-Hcl pH=6.3),进行非特异结合杂质的清洗,最后加入洗脱缓冲液(8M 尿素,100mM NaH2PO4,100mM Tris-Hcl pH=4.5)进行洗脱,收集洗脱目的蛋白,将洗脱后的目的蛋白以含0.1mol/L的GSH和0.1mol/L的GSSG洗脱缓冲液(100mM NaH2PO4,100mM Tris-HclpH=8.0)在4℃条件下以1:20的体积进行透析,2h换一次透析液,5次后,用洗脱缓冲液(100mM NaH2PO4,100mM Tris-Hcl pH=8.0)透析,全过程无沉淀产生。透析后样品的SDS-PAGE鉴定蛋白纯度在95%以上。对诱导后未处理的包涵体、诱导后粗纯的包涵体和诱导后纯化的包涵体进行SDA-PAGE分析,结果如图3所示:M为标准蛋白分子1、诱导后未处理的包涵体混合物,2、诱导后,包涵体洗涤粗纯的结果,3、诱导后粗纯完的样品上柱纯化后结果,由结果可知最终纯化后其本上除出了所有杂蛋白。
实施例3
人表皮生长因子hEGF生物学活性验证
将购买的Balb/c 3T3细胞(购自ATCC公司)传至3-4代,计数后,然后铺96孔板,每孔1×105个细胞。在96孔板DMEM完全培养基中(10%的血清)培养24小时后,加入维持培养基(0.4%的血清)中继续培养24小时。
hEGF(终浓度为20ng/mL),分别加对照组NC和EGF标准品(终浓度为20ng/mL)小肽刺激小鼠胚胎成纤维细胞Balb/c 3T3细胞72小时后,通过MTT法检测hEGF促进细胞增殖作用。酶标仪在450nm波长下检测吸光度,吸光度值与细胞增殖活性成正比。计算出比活性为6.1×107IU。结果见表1与图4,hEGF处理组增殖效果明显优于对照组,与标准样品相当。
表1hEGF细胞活性MTT法检测结果统计
*表示EGF处理组与对照组比较,具有显著性差异。
SEQUENCE LISTING
<110> 江苏迈健生物科技发展股份有限公司
<120> 人表皮生长因子hEGF基因优化序列及其制备方法和应用
<130> 20170615
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 159
<212> DNA
<213> 人工序列
<400> 1
aacagcgact ctgaatgccc actgtcccac gatggttact gcctgcatga tggtgtgtgc 60
atgtatattg aagctctgga caagtatgca tgcaattgtg ttgtaggcta catcggcgag 120
cgttgtcaat accgtgacct gaaatggtgg gaactgcgc 159
Claims (9)
1.人表皮生长因子hEGF基因优化序列,其特征在于:所述序列如SEQIDNO.1所示。
2.权利要求1所述的人表皮生长因子hEGF基因优化序列的制备方法,其特征在于:包括以下步骤:
步骤1,在基因数据库中获取人表皮生长因子hEGF基因;
步骤2,基因优化:对人表皮生长因子hEGF基因的编码区进行大肠杆菌密码子偏爱性的基因优化得到优化序列,优化序列编码的氨基酸与人表皮生长因子hEGF基因编码形成的氨基酸序列一致;
步骤3,添加酶切位点:在优化序列的5’端添加一种内切酶的酶切位点,在优化序列的3’端添加另一种内切酶酶切位点,得到合成序列;
步骤4,基因合成:对得到的合成序列进行全基因合成。
3.根据权利要求2所述的人表皮生长因子hEGF基因优化序列的制备方法,其特征在于:在步骤3中,优化序列的5’端添加NdeI酶切位点,优化序列的3’端添加XhoI酶切位点。
4.含有权利要求1所述的人表皮生长因子hEGF基因优化序列的质粒。
5.根据权利要求4所述的含有权利要求1所述的人表皮生长因子hEGF基因优化序列的质粒,其特征在于:所述质粒为 pET-30a质粒 。
6.根据权利要求5所述的含有权利要求1所述的人表皮生长因子hEGF基因优化序列的质粒,其特征在于:权利要求1所述的人表皮生长因子hEGF基因优化序列***到pET-30a质粒的 Nde I 酶切位点和 Xho I 酶切位点之间。
7.含有权利要求1所述的人表皮生长因子hEGF基因优化序列的原核生物。
8.根据权利要求7所述的含有权利要求1所述的人表皮生长因子hEGF基因优化序列的原核生物,其特征在于:所述原核生物为大肠杆菌。
9.权利要求1所述的人表皮生长因子hEGF基因优化序列表达得到的人表皮生长因子hEGF在制备护肤品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710451539.2A CN107254472A (zh) | 2017-06-15 | 2017-06-15 | 人表皮生长因子hEGF基因优化序列及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710451539.2A CN107254472A (zh) | 2017-06-15 | 2017-06-15 | 人表皮生长因子hEGF基因优化序列及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107254472A true CN107254472A (zh) | 2017-10-17 |
Family
ID=60023205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710451539.2A Pending CN107254472A (zh) | 2017-06-15 | 2017-06-15 | 人表皮生长因子hEGF基因优化序列及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107254472A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111073893A (zh) * | 2019-12-28 | 2020-04-28 | 河北柯瑞生物医药有限公司 | 一种重组短肽、其生产方法及其促创面愈合的应用 |
CN112941132A (zh) * | 2021-05-17 | 2021-06-11 | 烟台市华昕生物医药科技有限公司 | 一种利用大肠杆菌表达寡肽-1的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102978231A (zh) * | 2012-08-02 | 2013-03-20 | 天津强微特生物科技有限公司 | 一种重组人表皮生长因子工程菌的构建和筛选方法 |
AU2009206089B2 (en) * | 2008-01-15 | 2014-08-28 | Abbvie Inc. | Improved mammalian expression vectors and uses thereof |
CN105463006A (zh) * | 2014-09-12 | 2016-04-06 | 尹成凯 | 重组人表皮生长因子的新型制备方法 |
-
2017
- 2017-06-15 CN CN201710451539.2A patent/CN107254472A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009206089B2 (en) * | 2008-01-15 | 2014-08-28 | Abbvie Inc. | Improved mammalian expression vectors and uses thereof |
CN102978231A (zh) * | 2012-08-02 | 2013-03-20 | 天津强微特生物科技有限公司 | 一种重组人表皮生长因子工程菌的构建和筛选方法 |
CN105463006A (zh) * | 2014-09-12 | 2016-04-06 | 尹成凯 | 重组人表皮生长因子的新型制备方法 |
Non-Patent Citations (2)
Title |
---|
DAVID RHYS THOMAS等: "Improved expression of recombinant plant-made hEGF", 《PLANT CELL REP》 * |
张海淼等: "人表皮生长因子融合蛋白的表达及纯化工艺的优化", 《中国生物工程杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111073893A (zh) * | 2019-12-28 | 2020-04-28 | 河北柯瑞生物医药有限公司 | 一种重组短肽、其生产方法及其促创面愈合的应用 |
CN112941132A (zh) * | 2021-05-17 | 2021-06-11 | 烟台市华昕生物医药科技有限公司 | 一种利用大肠杆菌表达寡肽-1的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110845603A (zh) | 人胶原蛋白17型多肽、其生产方法和用途 | |
CN113087804B (zh) | 一种二价植物免疫融合蛋白及其生产方法和应用 | |
CN107254472A (zh) | 人表皮生长因子hEGF基因优化序列及其制备方法和应用 | |
CN101302526A (zh) | 重组可溶性溶血链球菌溶血素o基因、重组蛋白及其制备方法 | |
CN103710367B (zh) | 一种重组人激肽释放酶1及其编码基因和制备方法 | |
CN103193887B (zh) | 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法 | |
CN102021173B (zh) | 可溶性截短的人trail活性蛋白的制备方法 | |
CN108368512B (zh) | 一种重组人粒细胞集落刺激因子的制备方法 | |
CN104603280A (zh) | 生产多肽的方法 | |
CN107254481A (zh) | 人重组表皮生长因子MJ‑hEGF基因优化序列及其制备方法和应用 | |
CN105177033A (zh) | 利用pSUMO***制备碱性成纤维细胞生长因子的方法 | |
CN107435045B (zh) | 一种优化重组人白细胞介素-2的核苷酸序列及高效可溶性表达方法 | |
CN108484749B (zh) | 一种重组可溶性人源骨靶向干扰素γ-1b及其制备方法 | |
CN107556376B (zh) | 一种干扰素α-2b突变体及其制备方法和应用 | |
CN110004153A (zh) | 鸡重组CEBPγ蛋白、其编码DNA序列及应用 | |
CN103397038B (zh) | 一种人白细胞介素-38的生产方法 | |
CN104130996B (zh) | 关节炎型支原体精氨酸脱亚胺酶突变体及其应用 | |
CN108300725B (zh) | 可溶性单链抗体超抗原融合基因及蛋白和其制备与应用 | |
CN101608179B (zh) | 融合肝素酶及其编码基因 | |
CN112646044B (zh) | TFF2-Fc融合蛋白及其高效表达生产方法 | |
CN114908113A (zh) | 人白细胞介素-5重组蛋白的制备方法 | |
CN101433713A (zh) | GnRH-PE突变体融合蛋白及其用途 | |
CN116478969A (zh) | 胶原酶突变体、促进重组胶原酶分泌表达的方法及其应用 | |
CN105602977A (zh) | 高活性人细胞因子Eotaxin-2的制备方法及应用 | |
CN102391377A (zh) | 一种可诱导和激活癌靶向t细胞的融合蛋白及制备方法及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171017 |
|
RJ01 | Rejection of invention patent application after publication |